{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:13:55Z","timestamp":1793276035186,"version":"4.5.0"},"reference-count":23,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Friends of Cancer Research","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,8,27]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Circulating tumor DNA (ctDNA) is a promising intermediate end point for oncology drug development, potentially accelerating regulatory approvals by providing early insights into treatment response. However, challenges remain in standardizing ctDNA assessment, including optimal blood collection timing and defining molecular response (MR) cutoffs. The ctDNA for Monitoring Treatment Response (ctMoniTR) project, led by Friends of Cancer Research, aggregates patient-level data from clinical trials to evaluate associations between ctDNA changes and overall survival (OS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This analysis included four randomized clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) treated with either anti-programmed death (ligand) 1 (anti-PD(L)1) therapy (with or without chemotherapy) or chemotherapy alone. MR was assessed using three predefined per cent-change thresholds in ctDNA levels (\u226550% decrease, \u226590% decrease, and 100% clearance). ctDNA samples were analyzed at two timepoints: an early window (T1, up to 7 weeks post-treatment initiation) and a later window (T2, 7\u201313 weeks post-treatment initiation). Multivariable Cox proportional hazards models and time-dependent analyses were used to evaluate associations between ctDNA changes and OS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 918 patients were included. In the anti-PD(L)1 group, ctDNA reductions at both T1 and T2 were significantly associated with improved OS across all MR thresholds. In the chemotherapy group, associations were weaker at T1 but became more pronounced at T2. Patients with MR at both T1 and T2 had the strongest OS associations. Overall, the results suggest that T2 had marginally stronger association with OS than T1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study supports the potential of ctDNA as an intermediate end point in aNSCLC, with MR at both early (T1) and later (T2) timepoints showing significant associations with OS. Differences in ctDNA dynamics between treatment modalities highlight the importance of considering the timing of blood collection. Further research is needed to determine the optimal time window for assessing ctDNA response. Prospective trials and trial-level meta-analyses will be critical to validating ctDNA as a regulatory-grade intermediate end point for oncology drug development.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2025-012454","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:40:17Z","timestamp":1758519617000},"page":"e012454","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and\/or chemotherapy"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0177-2024","authenticated-orcid":false,"given":"Hillary S","family":"Andrews","sequence":"first","affiliation":[{"name":"Friends of Cancer Research, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevine","family":"Zariffa","sequence":"additional","affiliation":[{"name":"NMD Group Inc, Bala Cynwyd, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine K","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Cancer Research And Biostatistics, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Deng","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Eisele","sequence":"additional","affiliation":[{"name":"Cancer Research And Biostatistics, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Ensor","sequence":"additional","affiliation":[{"name":"Natera Inc, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin","family":"Espenschied","sequence":"additional","affiliation":[{"name":"Guardant Health Inc, Redwood City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fabrizio","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M","family":"Goren","sequence":"additional","affiliation":[{"name":"Cancer Research And Biostatistics, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Haddad","sequence":"additional","affiliation":[{"name":"AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minetta C","family":"Liu","sequence":"additional","affiliation":[{"name":"Natera Inc, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimple","family":"Modi","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim K","family":"Moesta","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie J","family":"Quinn","sequence":"additional","affiliation":[{"name":"Guardant Health Inc, Redwood City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Cancer Research And Biostatistics, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6173-6957","authenticated-orcid":false,"given":"Diana Merino","family":"Vega","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zou","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Hoering","sequence":"additional","affiliation":[{"name":"Cancer Research And Biostatistics, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4847-0736","authenticated-orcid":false,"given":"Mark","family":"Stewart","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Allen","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,21]]},"reference":[{"key":"2025092122401254000_13.9.e012454.1","unstructured":"FDA Center for Drug Evaluation and Research . Guidance for Industry: Expedited Program for Serious Conditions-Accelerated Approval of Drugs and Biologics. 2014. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/expedited-programs-serious-conditions-drugs-and-biologics"},{"key":"2025092122401254000_13.9.e012454.2","unstructured":"FDA Oncology Center of Excellence . Use of Circulating Tumor DNA for Curative-Intent Solid Tumor Drug Development: Guidance for Industry. 2024. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-circulating-tumor-deoxyribonucleic-acid-early-stage-solid-tumor-drug-development-guidance"},{"key":"2025092122401254000_13.9.e012454.3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/1078-0432.CCR-23-1469","article-title":"Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer","volume":"30","author":"Murray","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025092122401254000_13.9.e012454.4","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00372","article-title":"Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors","volume":"6","author":"Vega","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2025092122401254000_13.9.e012454.5","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/1078-0432.CCR-24-3612","article-title":"ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials","volume":"31","author":"Andrews","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2025092122401254000_13.9.e012454.6","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/PO.20.00321","article-title":"Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy","volume":"5","author":"Thompson","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2025092122401254000_13.9.e012454.7","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy137"},{"key":"2025092122401254000_13.9.e012454.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"2025092122401254000_13.9.e012454.9","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"2025092122401254000_13.9.e012454.10","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-019-01624-z"},{"key":"2025092122401254000_13.9.e012454.11","doi-asserted-by":"crossref","unstructured":"Akaike H . Information Theory and an Extension of the Maximum Likelihood Principle. Biogeochemistry 1998;199\u2013213. doi:10.1007\/978-1-4612-1694-0_15","DOI":"10.1007\/978-1-4612-1694-0_15"},{"key":"2025092122401254000_13.9.e012454.12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1214\/aos\/1176344136","article-title":"Estimating the Dimension of a Model","volume":"6","author":"Schwarz","year":"1978","journal-title":"Ann Statist"},{"key":"2025092122401254000_13.9.e012454.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1982.03320430047030"},{"key":"2025092122401254000_13.9.e012454.14","doi-asserted-by":"publisher","DOI":"10.1214\/aoms\/1177732360"},{"key":"2025092122401254000_13.9.e012454.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025092122401254000_13.9.e012454.16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1127"},{"key":"2025092122401254000_13.9.e012454.17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-1718"},{"key":"2025092122401254000_13.9.e012454.18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005344","article-title":"Regulatory Implications of ctDNA in Immuno-oncology for Solid Tumors","volume":"11","author":"Vellanki","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025092122401254000_13.9.e012454.19","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1158\/1538-7445.AM2023-2299","article-title":"Abstract 2299: Misclassification of Clonal Hematopoietic Mutations as Tumor-Derived Confound Accurate ctDNA-Response Assessment in Patients with Metastatic Non-Small-Cell Lung Cancer: Analyses from the Phase 3 MYSTIC Trial","volume":"83","author":"Abbosh","year":"2023","journal-title":"Cancer Res"},{"key":"2025092122401254000_13.9.e012454.20","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/cncr.34168","article-title":"Reporting on Circulating Tumor DNA Monitoring in Metastatic Cancer-From Clinical Validity to Clinical Utility","volume":"128","author":"Brenner Thomsen","year":"2022","journal-title":"Cancer"},{"key":"2025092122401254000_13.9.e012454.21","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/s41416-023-02445-1","article-title":"Molecular Response Assessment using Circulating Tumor DNA (ctDNA) in Advanced Solid Tumors","volume":"129","author":"Thompson","year":"2023","journal-title":"Br J Cancer"},{"key":"2025092122401254000_13.9.e012454.22","unstructured":"Friends of Cancer Research . Framework for Integrating Change in ctDNA Levels in Advanced Cancer Clinical Trials to Support Meta-Analyses for Intermediate Endpoint Validation. 2024. Available: https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/Framework-for-Integrating-Change-in-ctDNA-Levels-in-Advanced-Cancer-Clinical-Trials-to-Support-Meta-analyses-for-Intermediate-Endpoint-Validation.pdf"},{"key":"2025092122401254000_13.9.e012454.23","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1058220","article-title":"Circulating Tumor DNA: Opportunities and Challenges for Pharmacometric Approaches","volume":"13","author":"Ribba","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:40:20Z","timestamp":1758519620000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,21]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/jitc-2025-012454"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012454","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}